Merck & Co., Inc., Rahway, NJ, USA (United States)

Papers in the tracked journals with an author at Merck & Co., Inc., Rahway, NJ, USA (United States): per year and category, where they are published, the institutions its researchers write with, and its most-cited papers. A paper counts as corporate when at least one of its authors is affiliated with an institution that OpenAlex classifies as a company; it counts once for each company among its authors' affiliations. Universities are the institutions OpenAlex classifies as education. Also as Markdown.

← Corporate research

Key findings#

From 2017 to 2026 (so far), authors at Merck & Co., Inc., Rahway, NJ, USA (United States) took part in 62 papers in the tracked journals, most of them in health economics and policy (50), statistics (9) and AI (2).
5 of them were published in 2025, against 4 in 2017.
Since 2023, the institutions with the most of these papers were Adelphi Group (United Kingdom) (3), Analysis Group (United States) (3) and MSD (Switzerland) (3).
The journals publishing most of them were PharmacoEconomics (6), PharmacoEconomics - Open (6) and Health Economics Review (3).
The most-cited of them is “Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States” (PharmacoEconomics, 2017), with 142 citations.
Since 2023, papers in the tracked journals cited 24 of its papers 56 times; 96% of those links came from papers with a university author and 14% from its own papers.
Its own papers since 2023 cite archived papers 30 times, 53% of them papers with a company author.
Across everything OpenAlex indexes, Merck & Co., Inc., Rahway, NJ, USA (United States) has 41,964 works with 9,396,899 citations (h-index 923).
The tracked journals hold 53 of its 13,629 works in OpenAlex from 2017 to 2025 (0.4%).
Its main research topics in OpenAlex are Cancer Immunotherapy and Biomarkers (2,973), Pharmacogenetics and Drug Metabolism (1,654) and Statistical Methods in Clinical Trials (1,589).

Papers per year#

20172026 (so far)

Papers per publication year and category
Category	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026 (so far)
Health Economics and Policy	4	1	5	5	8	8	3	3	5	8
Statistics	0	2	0	0	2	2	1	1	0	1
AI	0	0	0	0	0	1	0	1	0	0
Economics	0	0	0	1	0	0	0	0	0	0
All categories	4	3	5	6	10	11	4	5	5	9

Where the papers come from#

Journals with the most papers, since 2023
#	Journal	Papers
1	PharmacoEconomics	6
2	PharmacoEconomics - Open	6
3	Health Economics Review	3
4	Applied Health Economics and Health Policy	2
5	Computational Statistics & Data Analysis	1
6	Statistical Papers	1
7	Computational Statistics	1
8	Health Research Policy and Systems	1
9	Cost Effectiveness and Resource Allocation	1
10	Nature Machine Intelligence	1

Institutions with the most papers, since 2023
#	Institution	Papers
1	Adelphi Group (United Kingdom)	3
2	Analysis Group (United States)	3
3	MSD (Switzerland)	3
4	University of Sheffield	3
5	Duke Medical Center	2
6	Duke University	2
7	MSD (UK) Limited (United Kingdom)	2
8	University of Arkansas for Medical Sciences	2
9	University of Maryland, Baltimore	2

Countries with the most papers, since 2023
#	Country	Papers
1	United States	23
2	United Kingdom	9
3	Switzerland	4
4	Germany	2
5	Canada	1
6	China	1
7	Japan	1
8	Portugal	1
9	Sweden	1

Keywords with the most papers, since 2023
#	Keyword	Papers
1	quality-adjusted life years	8
2	cost-effectiveness	6
3	health care costs	5
4	economic burden	4
5	health utility	4
6	pulmonary arterial hypertension	4
7	COVID-19 pandemic	3
8	adults	3
9	disease severity	3
10	health technology assessment	3

Most-cited papers#

Most-cited papers since 2017
#	Citations	Per month	Title	Journal	Published	Authors
1	142	1.3	Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States	PharmacoEconomics	2017-06-15	Min Huang, Yanyan Lou, James M. Pellissier et al.
2	46	0.8	Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review	PharmacoEconomics	2022-02-02	Min Huang, Amin Haiderali, Grace E. Fox et al.
3	43	0.4	Direct Medical Costs of Type 2 Diabetes in France: An Insurance Claims Database Analysis	PharmacoEconomics - Open	2017-08-07	Bernard H. Charbonnel, D. Simon, Jean Dallongeville et al.
4	41	0.8	Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US	PharmacoEconomics	2022-07-01	Hardik Goswami, Adnan Alsumali, Yiling Jiang et al.
5	39	0.5	An overview of critical decision-points in the medical product lifecycle: Where to include patient preference information in the decision-making process?	Health Policy	2020-07-29	Chiara L. Whichello, Karin Schölin Bywall, Jonathan Mauer et al.
6	34	0.4	Cost Effectiveness of PD-L1-Based Test-and-Treat Strategy with Pembrolizumab as the First-Line Treatment for Metastatic NSCLC in Hong Kong	PharmacoEconomics - Open	2019-09-17	Herbert Ho-Fung Loong, Carlos King Ho Wong, Linda Kam Suet Leung et al.
7	34	0.6	Should we screen for lung cancer? A 10-country analysis identifying key decision-making factors	Health Policy	2022-06-07	Charlotte Poon, Artes Haderi, Alexander Roediger et al.
8	32	0.4	Optimal control of prevention and treatment in a basic macroeconomic–epidemiological model	Mathematical Social Sciences	2020-04-25	Davide La Torre, Tufail M. Malik, Simone Marsiglio
9	32	0.5	Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective	PharmacoEconomics	2021-10-08	Adnan Alsumali, Laurence M. Djatche, Andrew H. Briggs et al.
10	32	1.3	A call for an industry-led initiative to critically assess machine learning for real-world drug discovery	Nature Machine Intelligence	2024-10-04	Cas Wognum, Jeremy R. Ash, Matteo Aldeghi et al.

Who cites its research#

Institutions whose papers cite it most, since 2023
#	Institution	Kind	Country	Links
1	SKEMA Business School	University	France	7
2	Université Côte d'Azur	University	France	7
3	University of Pisa	University	Italy	6
4	University of Groningen	University	Netherlands	5
5	University of Toronto	University	Canada	4
6	University of Sheffield	University	United Kingdom	4
7	University of Alberta	University	Canada	3
8	University of Milan	University	Italy	3
9	Erasmus University Rotterdam	University	Netherlands	3

What its papers cite#

Institutions its papers cite most, since 2023
#	Institution	Kind	Country	Links
1	University of Sheffield	University	United Kingdom	7
2	University of Basel	University	Switzerland	3
3	Analysis Group (United States)	Company	United States	3
4	The University of Melbourne	University	Australia	2
5	Duke University	University	United States	2
6	Bielefeld University	University	Germany	2
7	University of Oxford	University	United Kingdom	2
8	Office Of Health Economics	Government	United Kingdom	2
9	Duke Medical Center	Healthcare	United States	2

Citation links inside the tracked journals; see the corporate citation network and industry–university links.

In OpenAlex#

Merck & Co., Inc., Rahway, NJ, USA (United States) in OpenAlex
Item	Value
Type	Company
Location	Rahway, New Jersey, United States
Also known as	MSD, MSD United States, Merck & Co., Inc., Rahway, NJ, USA
Units listed in OpenAlex	29
Works in OpenAlex	41,964
Citations	9,396,899
h-index	923
i10-index	100,677
2-year mean citedness	6.16
Website	www.merck.com
ROR	ror.org/02891sr49
OpenAlex	openalex.org/I1285764155

Main research topics (OpenAlex, all works)
#	Topic	Field	Works
1	Cancer Immunotherapy and Biomarkers	Medicine	2,973
2	Pharmacogenetics and Drug Metabolism	Pharmacology, Toxicology and Pharmaceutics	1,654
3	Statistical Methods in Clinical Trials	Mathematics	1,589
4	Health Systems, Economic Evaluations, Quality of Life	Economics, Econometrics and Finance	1,582
5	Analytical Methods in Pharmaceuticals	Chemistry	1,561

Works and citations per year in OpenAlex, and its papers in the tracked journals
Year	Works in OpenAlex	Citations received	In the tracked journals	Share
2026 (so far)	1,313	99,904	9	0.7%
2025	1,619	126,960	5	0.3%
2024	1,678	131,370	5	0.3%
2023	1,629	126,413	4	0.2%
2022	1,677	125,614	11	0.7%
2021	1,583	126,520	10	0.6%
2020	1,599	112,690	6	0.4%
2019	1,373	94,422	5	0.4%
2018	1,258	86,973	3	0.2%
2017	1,213	81,863	4	0.3%

From OpenAlex's own record of the institution (CC0), read again monthly. Works and citations count everything OpenAlex indexes, not only the tracked journals; topics are OpenAlex's classification of those works.

Cite this page

Scholar4AI. (2026). Merck & Co., Inc., Rahway, NJ, USA (United States). Journal and Conference Research Rankings. Retrieved November 4, 2026, from https://scholar4ai.com/companies/merck-co-inc-rahway-nj-usa-united-states

@misc{scholar4ai-companies-merck-co-inc-rahway-nj-usa-united-states,
  author = {{Scholar4AI}},
  title = {Merck & Co., Inc., Rahway, NJ, USA (United States)},
  year = {2026},
  howpublished = {\url{https://scholar4ai.com/companies/merck-co-inc-rahway-nj-usa-united-states}},
  urldate = {2026-11-04},
  note = {Journal and Conference Research Rankings; data from OpenAlex (CC0); licensed CC BY-NC 4.0}
}

Free to reuse for non-commercial purposes with attribution (CC BY-NC 4.0).